Last reviewed · How we verify
Uncomplicated Skin and Skin Structure Infections
Approved treatments
- Cefpodoxime Proxetil · Pfizer
- Test formulation (Treatment A) · Pfizer
Clinical guidelines
- FDA label — 1L
Linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Uncomplicated Skin and Skin Structure Infections patent landscape — cliff calendar, originator estates, attackable patents
- Uncomplicated Skin and Skin Structure Infections treatment landscape brief
- Uncomplicated Skin and Skin Structure Infections treatment updates RSS
Frequently asked questions about Uncomplicated Skin and Skin Structure Infections
What drugs treat Uncomplicated Skin and Skin Structure Infections?
Tracked treatments include Cefpodoxime Proxetil, Test formulation (Treatment A).
What is the treatment for Uncomplicated Skin and Skin Structure Infections?
Standard treatment for Uncomplicated Skin and Skin Structure Infections includes Cefpodoxime Proxetil, Test formulation (Treatment A). See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Uncomplicated Skin and Skin Structure Infections?
FDA label publishes guidelines for Uncomplicated Skin and Skin Structure Infections. 1 guideline references tracked.
Related
- Treatment landscape: Uncomplicated Skin and Skin Structure Infections patent cliff · Uncomplicated Skin and Skin Structure Infections CI report
- Treatment: Cefpodoxime Proxetil · Pfizer
- Treatment: Test formulation (Treatment A) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing